A Study to Evaluate Alzheimer Disease Biomarkers in Cerebrospinal Fluid (CSF)


About this study

The purpose of this study is to validate the Alzheimer Disease Biomarkers assays (Phospho-Tau/Total-Tau/Ab42) being implemented at Mayo to compare them to the referral tests in support of test validation efforts.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Patients undergoing a spinal tab for CSF collection and in whom the referral test ADmark Phospho-Tau/Total-Tau/Ab42 has been ordered.

Exclusion Criteria: 

  • All subjects not meeting inclusion criteria

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Open for enrollment

Contact information:

Mohamed Ibrahim



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available